Setbacks For China Pharma As Firms Hit With Antitrust Fine, Clinical Setback
One of China's largest domestic pharma conglomerates has been fined more than $100m for price-fixing and other monopoly acts, while another firm has seen a major Phase III setback for its global launch hope.
You may also be interested in...
Despite administering a total of 2.2 billion COVID-19 shots, China as the first country to experience the coronavirus outbreak has yet to open its borders, while more effective mRNA vaccines are still nowhere to be found amid apparent delays for the licensed-in lead candidate.
Despite multiple challenges including pricing pressures and slowing general economic growth, China offers attractive opportunities for emerging biopharma firms, helped by an encouraging regulatory environment. But weighing up options around challenging areas including partnering is essential, a new report states.
The latest development over the licensing arrangement for the anticancer drug may deal a further blow to BeiGene’s oncology commercial efforts in China.